In his recent presentation at IDWeek 2024, Sean N. Tucker, PhD, Chief Scientific Officer and Vice President of Research at Vaxart, unveiled promising clinical trial results regarding VXA-GI.1-NN, a potential breakthrough in the prevention of Norovirus infections. Norovirus is a significant global health concern, known as a leading cause of acute gastroenteritis. Yet, the healthcare industry has grappled with the absence of specific treatment for Norovirus gastroenteritis (NVG). The development of VXA-GI.1-NN, a nonreplicating adenovirus-vectored thermostable oral vaccine, thus signifies a leap forward in not just treating, but preventing NVG.
According to Dr. Tucker, recent trials of VXA-GI.1-NN have demonstrated its safety, tolerance, and effective additional capacity to generate robust cellular and serum immune responses. These resulted in a considerable reduction in Norovirus infection incidences, positioning VXA-GI.1-NN as a potentially potent prevention measure for a wide and diverse demographic. The clinical evidence notably indicated an 85% reduction in geometric mean viral shedding in stool samples among participants who received the vaccine.
The ability of the vaccine to induce pronounced serum and cellular immunogenicity was also underlined by substantial growth of VP1 GI.1-specific antibody-secreting cells (ASC) and serum antibodies. The vaccine outperformed placebos in inducing higher serum functional antibody responses, as measured by the Norovirus Blocking Antibody Assay (NBAA). Furthermore, significant augmentations in VP1-specific IgA levels were observed in the nasal secretions and saliva of vaccinated participants.
In a significant strategic choice, the study focused on a demographic group of healthy adults between 18 to 49 years of age, ensuring safety due to the high dosages of the virus being administered. Dr. Tucker revealed early confidence in the efficacy of VXA-GI.1-NN among elderly populations, the demographic believed to gain the most benefit from the vaccine, despite their often waned immune responses. This confidence was reinforced by a prior study indicating similar elicited immune responses amongst younger and older participants.
The conducted randomized controlled trial involved 165 healthy adults divided between two groups, where one received a single oral dose of VXA-GI.1-NN vaccine and the other a placebo. On the 28th day post-vaccination, a specific strain of norovirus was introduced to 141 participants. Monitoring was carried out for side effects for one week, whereas adverse event tracking continued till 28 days post-exposure. Vaccine effectiveness was measured by monitoring cases of norovirus-caused acute gastroenteritis and quantifying norovirus presence in stool and vomit samples.
Key features of VXA-GI.1-NN that sets it apart from traditional vaccines include its oral tablet form delivery, designed towards stimulation of antibodies not just in serum but also intestinal space. As Norovirus primarily infects intestinal cells, this method of delivery is expected to enhance effectiveness. Looking ahead, preparations are underway for a Phase 2B study that would pave the way for initiating Phase 3 efficacy trials with the FDA.
Summarizing the breakthrough study findings, VXA-GI.1-NN has proven to be safe and immunogenic, showcasing a capability to reduce viral shedding and Norovirus infection. The lowered viral shedding might contribute significantly towards mitigating outbreaks, and point at the vaccine’s protective effect – with implications for evolving public health strategies against Norovirus outbreaks.